Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cardiac safety pharmacology: from human ether-a-gogo related gene channel block towards induced pluripotent stem cell based disease models.

Expert opinion on drug safety - 1 Mar 2012

Kraushaar Udo, Meyer Thomas, Hess Dietmar, Gepstein Lior, Mummery Christine L, Braam Stefan R, Guenther Elke

Abstract excerpt

INTRODUCTION: The field of cardiac safety pharmacology has been experiencing exciting changes over the recent years. Drug induced arrhythmia of the torsade des pointes types has been the reason for the denial of approval of novel drug candidates. The aim of cardiac safety pharmacology is to detect undesirable pharmacodynamic drug effects within and above the therapeutic range. A special focus is on the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Action Potentials
Share to Arrhythmias, Cardiac

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biological Assay

Share to ERG1 Potassium Channel

Share to Ether-A-Go-Go Potassium Channels

Share to Myocytes, Cardiac

Share to Patch-Clamp Techniques

Share to Toxicity Tests

Source

Identifiers

PMID: 22103746
DOI: 10.1517/14740338.2012.639358

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cardiac safety pharmacology: from human ether-a-gogo related gene channel block towards induced pluripotent stem cell based disease models.PMID 22103746Read ↗

Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity ScreeningSemantic proximity Read ↗

Induced pluripotent stem cell-derived cardiomyocytes: a versatile tool for arrhythmia research.Semantic proximity Read ↗

Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes.Semantic proximity Read ↗

Towards Precision Medicine With Human iPSCs for Cardiac ChannelopathiesSemantic proximity Read ↗

Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.Semantic proximity Read ↗

Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes as an in vitro model in toxicology: strengths and weaknesses for hazard identification and risk characterizationSemantic proximity Read ↗

Modeling long QT syndromes using induced pluripotent stem cells: current progress and future challenges.Semantic proximity Read ↗

Translational toxicology and rescue strategies of the hERG channel dysfunction: biochemical and molecular mechanistic aspects.Semantic proximity Read ↗

Induced pluripotent stem cells in the inherited cardiomyopathies: From disease mechanisms to novel therapies.Semantic proximity Read ↗

Clinical Trial in a Dish: Using Patient-Derived Induced Pluripotent Stem Cells to Identify Risks of Drug-Induced Cardiotoxicity.Semantic proximity Read ↗

Human iPSC-Derived Cardiomyocytes for Investigation of Disease Mechanisms and Therapeutic Strategies in Inherited Arrhythmia Syndromes: Strengths and LimitationsSemantic proximity Read ↗

Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell cultureSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.